Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Horizon Discovery Group PLC    HZD   GB00BK8FL363

HORIZON DISCOVERY GROUP PLC (HZD)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 07/17 05:35:15 pm
167 GBp   -2.20%
05/17HORIZON DISCOVE : Board Change
PU
05/16HORIZON DISCOVE : Annual Report and Notice of Annual General Meeting
PU
05/10BIOCENTURY - MA : GSK, Horizon
AQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
165.5(c) 166(c) 168.25(c) 170.75(c) 167 Last
29 046 74 997 1 622 027 58 732 61 453 Volume
-1.34% +0.30% +1.36% +1.49% -2.20% Change
More quotes
Financials (GBP)
Sales 2018 60,1 M
EBIT 2018 -2,13 M
Net income 2018 -2,53 M
Finance 2018 24,2 M
Yield 2018 -
Sales 2019 67,7 M
EBIT 2019 2,16 M
Net income 2019 0,78 M
Finance 2019 26,4 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 262,69
EV / Sales2018 3,76x
EV / Sales2019 3,31x
Capitalization 250 M
More Financials
Company
Horizon Discovery Group Plc is a gene editing company, which engages in the design and engineering of genetically-modified cells.The firm operates through the following business segments: Products, Services, and Leveraged Research and Development.The Products segment sells cell lines and other... 
More about the company
Surperformance© ratings of Horizon Discovery Group PL
Trading Rating : Investor Rating :
More Ratings
Latest news on HORIZON DISCOVERY GROUP PL
05/17HORIZON DISCOVERY : Board Change
PU
05/16HORIZON DISCOVERY : Annual Report and Notice of Annual General Meeting
PU
05/10BIOCENTURY - MANAGEMENT TRACKS : GSK, Horizon
AQ
05/10HORIZON DISCOVERY : Form 8.5 (EPT/RI)- Horizon Discovery Group plc
PU
05/10HORIZON DISCOVERY : Form 8.5 (EPT/RI) - Horizon Discovery Group PLC
PU
05/09Horizon Discovery Group plc Acknowledges Statement by Abcam
GL
05/09HORIZON DISCOVERY : Acknowledges Statement by Abcam
PU
05/09ABCAM : Horizon appoints new CEO and unveils impressive revenue growth
AQ
05/09HORIZON DISCOVERY : Form 8.3 - Horizon Discovery Group
PU
05/09ABCAM : Horizon Discovery's shares slump after UK's Abcam drops bid
RE
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/28Susan Galbraith, Head of in our IMED Biotech Unit, attended the ceremony fo..
6
06/20. has named our very own Susan Galbraith, Head of Oncology, IMED Biotech Unit..
3
06/14Dr Darrin Disley was appointed an OBE for his services to business, enterpris.. 
05/31Horizon Discovery's hold rating reiterated at Peel Hunt.  
05/17Horizon Discovery : Board Change  
More tweets
Qtime:50
Chart HORIZON DISCOVERY GROUP PL
Duration : Period :
Horizon Discovery Group PL Technical Analysis Chart | HZD | GB00BK8FL363 | 4-Traders
Technical analysis trends HORIZON DISCOVERY GROUP PL
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 2,37  GBP
Spread / Average Target 39%
EPS Revisions
Managers
NameTitle
Terrence William Pizzie Chief Executive Officer & Executive Director
Ian David Gilham Executive Chairman
Kim Nichols Head-Global Operations
Richard John Vellacott CFO, Secretary & Executive Director
Jonathan D. Moore Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
HORIZON DISCOVERY GROUP PLC-28.85%326
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147